Morrison & Foerster advised Phesi, Inc. (“Phesi”), a data-driven provider of AI-powered clinical development analytics products and solutions for biopharmaceutical companies around the world, in securing a $10 million investment from Sensyne Health (LSE: SENS) (“Sensyne”), a clinical AI technology company, as part of an exclusive strategic collaboration.
The investment will be used to accelerate Phesi’s and Sensyne’s product roadmaps. For Phesi, this means further development of its trial planning, protocol design, and investigator site selection platform, featuring ClinSite™. For Sensyne, this means the growth and ‘industrialization’ of its data platform, contributing to the company’s U.S. market growth strategy. The collaboration will see Sensyne’s anonymized real-world evidence data set of 6.1 million patients analyzed alongside Phesi’s data, which today covers 30 million clinical trial subjects. Together, the companies will provide an enhanced offering of clinical trial and real-world data predictive analytics, enabling life sciences organizations to quickly and safely determine the feasibility of replacing or supplementing a comparator or placebo arm with a synthetic arm.
The MoFo deal team advising Phesi was led by Boston Private Equity Investments + Buyouts of counsel Kevin Madden, with invaluable assistance from Palo Alto corporate associates Ophir Gam and Shiri Shenhav, along with New York partner Mitchell Presser, who is co-chair of MoFo’s Global Corporate Department, London corporate partner Simon Arlington, Boston Technology Transactions partner Matthew Karlyn, San Francisco Executive Compensation partner Amanda Hines Gold and London Tax partner Trevor James.